Nextkidney and Debiotech join forces — new CEO appointed to bring NeoKidney to market
Nextkidney BV and Swiss medtech company Debiotech join forces in NextKidney SA, appointing Jérôme Augustin as CEO to lead commercialisation of the NeoKidney — the world's first truly portable home hemodialysis device.
In June 2020, Nextkidney BV and Swiss medtech company Debiotech announced the formation of NextKidney SA — a combined entity dedicated to finalising development and commercialisation of the NeoKidney.
The NeoKidney is the world’s first truly portable home hemodialysis device. Using only 7 litres of fluid per treatment, it can be used anywhere — giving kidney patients the freedom to dialyse at home, on holiday or on the road, rather than being tied to hospital schedules three times a week.
Debiotech brings decades of miniaturised medical device expertise to the partnership, including a peritoneal dialysis machine licensed to Fresenius Medical Care. Jérôme Augustin was appointed CEO of the new combined company to lead the push to market.
The move marked a significant step forward for an initiative co-founded by the Dutch Kidney Foundation and backed by major Dutch health insurers CZ, Zilveren Kruis and Menzis — a unique model combining patient advocacy, clinical expertise and commercial ambition.
Why Commit Capital invested in Nextkidney backing the belief that truly portable dialysis is one of the highest-impact innovations in healthcare — improving quality of life for millions of patients worldwide while reducing systemic healthcare costs.